| Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic CancerPancreatic Cancer Organoids Parallel Patient Response H Tiriac, P Belleau, DD Engle, D Plenker, A Deschênes, TDD Somerville, ... Cancer discovery 8 (9), 1112-1129, 2018 | 896 | 2018 |
| Enhancer reprogramming promotes pancreatic cancer metastasis JS Roe, CI Hwang, TDD Somerville, JP Milazzo, EJ Lee, B Da Silva, ... Cell 170 (5), 875-888. e20, 2017 | 417 | 2017 |
| The metastasis associated protein S100A4: role in tumour progression and metastasis DM Helfman, EJ Kim, E Lukanidin, M Grigorian British journal of cancer 92 (11), 1955-1958, 2005 | 322 | 2005 |
| Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaGDC-0449 and … EJ Kim, V Sahai, EV Abel, KA Griffith, JK Greenson, N Takebe, GN Khan, ... Clinical cancer research 20 (23), 5937-5945, 2014 | 319 | 2014 |
| Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study PA Philip, J Lacy, F Portales, A Sobrero, R Pazo-Cid, JLM Mozo, EJ Kim, ... The lancet Gastroenterology & hepatology 5 (3), 285-294, 2020 | 209 | 2020 |
| A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer EJ Kim, E Ben‐Josef, JM Herman, T Bekaii‐Saab, LA Dawson, KA Griffith, ... Cancer 119 (15), 2692-2700, 2013 | 205 | 2013 |
| The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer EV Abel, EJ Kim, J Wu, M Hynes, F Bednar, E Proctor, L Wang, ... PloS one 9 (3), e91983, 2014 | 204 | 2014 |
| Characterization of the metastasis-associated protein, S100A4: roles of calcium binding and dimerization in cellular localization and interaction with myosin EJ Kim, DM Helfman Journal of Biological Chemistry 278 (32), 30063-30073, 2003 | 166 | 2003 |
| Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic CancerNivo Plus nab-Pac and Gem in Advanced Pancreatic Cancer ZA Wainberg, HS Hochster, EJ Kim, B George, A Kaylan, EG Chiorean, ... Clinical Cancer Research 26 (18), 4814-4822, 2020 | 116 | 2020 |
| Hedgehog signaling pathway and cancer therapeutics: progress to date JM Ruch, EJ Kim Drugs 73 (7), 613-623, 2013 | 95 | 2013 |
| Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature CellsEfficacy of Anti-DLL4 in Pancreatic Cancer WC Yen, MM Fischer, M Hynes, J Wu, E Kim, L Beviglia, VP Yeung, ... Clinical Cancer Research 18 (19), 5374-5386, 2012 | 84 | 2012 |
| Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F] αvβ6-Binding Peptide in Metastatic Carcinoma [18F] αvβ6-BP in Mice and Humans SH Hausner, RJ Bold, LY Cheuy, HK Chew, ME Daly, RA Davis, ... Clinical Cancer Research 25 (4), 1206-1215, 2019 | 78 | 2019 |
| Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers M Yarchoan, L Cope, AN Ruggieri, RA Anders, AM Noonan, LW Goff, ... Journal of Clinical Investigation 131 (24), e152670, 2021 | 65 | 2021 |
| First-in-human phase 1 dose escalation and expansion of a novel combination, anti-CSF-1 receptor (cabiralizumab) plus anti-PD-1 (nivolumab), in patients with advanced solid tumors Z Wainberg, S Piha-Paul, J Luke, E Kim, J Thompson, N Pfanzelter J Immunother Cancer 5 (89), 10.1186, 2017 | 56 | 2017 |
| Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models MJ Tu, PY Ho, QY Zhang, C Jian, JX Qiu, EJ Kim, RJ Bold, FJ Gonzalez, ... Cancer letters 442, 82-90, 2019 | 48 | 2019 |
| MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis MJ Tu, YZ Pan, JX Qiu, EJ Kim, AM Yu Oncotarget 7 (29), 45547, 2016 | 48 | 2016 |
| Neoadjuvant Immunotherapy–Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series R Demisse, N Damle, E Kim, J Gong, M Fakih, C Eng, L Oesterich, ... Journal of the National Comprehensive Cancer Network 18 (7), 798-804, 2020 | 45 | 2020 |
| Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline … PE Serrano, JM Herman, KA Griffith, MM Zalupski, EJ Kim, ... International Journal of Radiation Oncology* Biology* Physics 90 (2), 270-277, 2014 | 43 | 2014 |
| Phase 2 trial of neoadjuvant FOLFIRINOX and intensity modulated radiation therapy concurrent with fixed-dose rate-gemcitabine in patients with borderline resectable pancreatic … NH Tran, V Sahai, KA Griffith, H Nathan, R Kaza, KC Cuneo, J Shi, E Kim, ... International Journal of Radiation Oncology* Biology* Physics 106 (1), 124-133, 2020 | 39 | 2020 |
| Advances in pancreatic cancer EJ Kim, DM Simeone Current opinion in gastroenterology 27 (5), 460-466, 2011 | 38 | 2011 |
